Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics^TM, a new class of drugs for the treatment of multiple diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

We have a robust clinical-stage product pipeline that includes five mid- to late-stage product candidates, as well as preclinical programs. Our most advanced product candidates are in development for major depressive disorder, residual symptoms in schizophrenia, attention deficit/hyperactivity disorder (inattentive-predominant), Alzheimer’s disease and inflammatory disorders.

Targacept is located in Winston-Salem, North Carolina.

Targacept has several product candidates in clinical development. View our pipeline to learn more. On May 2, 2011, The Scientist magazine announced the winners of its 9th annual "Best Places to Work in Industry" survey... more..... At Targacept, the words “build” and “independence” have special meaning, as we are focused everyday on building health and restoring independence... more.... Watch the animation to find out how our drugs work in the nervous system.

January 05, 2012 Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s Disease January 04, 2012 Targacept to Present at the 30th Annual J.P. Morgan Healthcare Conference December 20, 2011 AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder December 05, 2011 Targacept Announces Initiation of Two Phase 2 Studies of TC-5619 June 10, 2011 Targacept Announces Closing of Over-allotment Option